| |
Cost-effectiveness Assessment of Telaprevir Combination Treatment Compared to Pegylated-Interferon + Ribavirin Alone
in the Management of Chronic Hepatitis C in Patients Who Failed a Prior Pegylated-Interferon + Ribavirin Treatment
|
| |
| |
Reported by Jules Levin
Presented at the 62nd Annual Meeting for the American Association for the Study of Liver Diseases, San Francisco, CA, USA, November 4-8 2011
Baris Deniz, MSc1; Anita J Brogan, PhD2; Jeffrey D Miller, MS3; Sandra E Talbird, MSPH2; James R Thompson, MS2
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States; 2RTI Health Solutions, Research Triangle Park, NC, United States; 3RTI Health Solutions, Waltham, MA, United States
|
|
| |
| |
|
|
|
